Por favor, use este identificador para citar o enlazar este ítem: https://doi.org/10.1016/j.biocel.2021.106059

Registro completo de metadatos
Campo DCValorLengua/Idioma
dc.contributor.authorLicari, Eugenia-
dc.contributor.authorSánchez del Campo Ferrer, Luis-
dc.contributor.authorFalletta, Paola-
dc.date.accessioned2024-12-16T08:39:37Z-
dc.date.available2024-12-16T08:39:37Z-
dc.date.issued2021-08-13-
dc.identifier.citationThe International Journal of Biochemistry & Cell Biology, Volumen: 139 , año: 2021es
dc.identifier.issn1357-2725-
dc.identifier.issn1878-5875-
dc.identifier.urihttp://hdl.handle.net/10201/147484-
dc.description©2021. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/ This document is the Published Manuscript version of a Published Work that appeared in final form in The International Journal of Biochemistry & Cell Biology. To access the final edited and published work see https://doi.org/10.1016/j.biocel.2021.106059es
dc.description.abstractIn recent years considerable progress has been made in identifying the impact of mRNA translation in tumour progression. Cancer cells hijack the pre-existing translation machinery to thrive under the adverse conditions originating from intrinsic oncogenic programs, that increase their energetic demand, and from the hostile microenvironment. A key translation program frequently dysregulated in cancer is the Integrated Stress Response, that reprograms translation by attenuating global protein synthesis to decrease metabolic demand while increasing translation of specific mRNAs that support survival, migration, immune escape. In this review we provide an overview of the Integrated Stress Response, emphasise its dual role during tumorigenesis and cancer progression, and highlight the therapeutic strategies available to target it.es
dc.formatapplication/pdfes
dc.format.extent8es
dc.languageenges
dc.publisherElsevieres
dc.relationÁmbito del proyecto: Europeo Agencia financiadora: Fundación Séneca, the Región de Murcia (FS-RM) (20809/PI/18), Ramon y Cajal Programme (RYC-2016-20036) y Fondazione Umberto Veronesies
dc.rightsinfo:eu-repo/semantics/openAccesses
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectIntegrated Stress Responsees
dc.subjecteIF2es
dc.subjectTranslation reprogramminges
dc.subjectCanceres
dc.subjectAdaptive/maladaptive-
dc.subjectISR activators-
dc.subjectISR inhibitors-
dc.titleThe two faces of the Integrated Stress Response in cancer progression and therapeutic strategieses
dc.typeinfo:eu-repo/semantics/articlees
dc.relation.publisherversionhttps://www.sciencedirect.com/science/article/pii/S1357272521001394es
dc.identifier.doihttps://doi.org/10.1016/j.biocel.2021.106059-
dc.contributor.departmentDepartamento de Bioquímica y Biología Molecular Aes
Aparece en las colecciones:Artículos

Ficheros en este ítem:
Fichero Descripción TamañoFormato 
1-s2.0-S1357272521001394-main (4).pdf2,44 MBAdobe PDFVista previa
Visualizar/Abrir


Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons